Navigation Links
DUSA Pharmaceuticals to Present at the 4th Annual Maxim Group Growth Conference
Date:11/11/2010

WILMINGTON, Mass., Nov. 11, 2010 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.® (Nasdaq GM: DUSA), a dermatology company that is developing and marketing Levulan® Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, announced that Bob Doman, President and Chief Executive Officer, will present a corporate overview at the 4th Annual Maxim Group Growth Conference on Thursday, November 18, 2010 at 8:30 a.m. ET at The Grand Hyatt Hotel in New York City.  Interested parties can access the live audio webcast of the presentation at www.dusapharma.com. An archived version of the presentation will be available on the DUSA website for 90 days following the presentation.

About DUSA Pharmaceuticals

DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan® PDT technology platform, and other dermatology products.  Levulan® Kerastick® for topical solution plus DUSA's BLU-U® blue light photodynamic therapy illuminator is currently approved for the treatment of minimally to moderately thick actinic keratoses (AKs) of the face or scalp.  DUSA also markets other dermatology products, including ClindaReach®.  DUSA is based in Wilmington, Mass.  Please visit our website at www.dusapharma.com.


'/>"/>
SOURCE DUSA Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... N.Y. , Jan. 23, 2017 LifeVac, ... from a blocked airway and prevented choking deaths, welcomes ... awareness advocate to the LifeVac team as Official Spokesperson. ... Steve join the LifeVac team," said Arthur Lih ... positioned to represent LifeVac and his mission to raise ...
(Date:1/23/2017)... , Jan 23, 2017 Research and Markets has ... & Trends - Product - Forecast to 2025" report to their ... Report Highlights: ... future market trends to identify the investment opportunities Market ... Key market trends across the business segments, Regions and Countries ...
(Date:1/23/2017)... January 23, 2017 Stock-Callers.com today presents ... (NASDAQ: CPRX ), Sophiris Bio Inc. (NASDAQ: ... ), and Agile Therapeutics Inc. (NASDAQ: AGRX ). ... somewhat lower in late trade on Friday, January 20 th ... 0.3%, while shares of health care companies in the S&P ...
Breaking Medicine Technology:
(Date:1/23/2017)... GREENVILLE, SC (PRWEB) , ... January 23, 2017 ... ... which is the premiere organization in North America for the scientific development, healthcare ... its 2017 Annual Scientific Session, and its 2017 AAT Member Certification Qualification Courses ...
(Date:1/23/2017)... ... January 23, 2017 , ... Steviva Ingredients, makers of all-natural ... USDA National Organic Program (NOP) for its Portland SQF Level 2 manufacturing facility. ... and handling systems to complement our current rigorous food-safety management systems,” said Yishu ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... general gynecological care and gynecological services for women of all ages. ... for a wide variety of reproductive services from routine health screenings to diagnosing ...
(Date:1/23/2017)... ... ... “Life Under Blankets”: an entrancing story about one woman's travels through the ... creation of published author, Kimberly Mitchell, who earned her bachelor’s degree in English education ... a master’s degree in education in the field of curriculum and instruction. Kimberly’s passion ...
(Date:1/22/2017)... Boca Raton, FL (PRWEB) , ... January 22, 2017 , ... ... products to customers across the world, recently met with big-name retail buyers at the ... strong scientific evidence of efficacy and uses the utmost safety standards in all of ...
Breaking Medicine News(10 mins):